To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Sufentanil is a synthetic opioid analgesic drug approximately 5 to 10 times more potent than fentanyl. Sufentanil is marketed for use by specialist centres under different trade names, such as Sufenta and Sufentil (India, by Claris Lifesciences Ltd.). Sufentanil was discovered at Janssen Pharmaceutica.
The main use of this medication is in operating suites and critical care where pain relief is required for a short period of time. It also offers properties of sedation and this makes it a good analgesic component of anaesthetic regimen during an operation. It is usually administered under the doctor's order through an intravenous route. In some countries sufentanil is only indicated for epidural use, despite this, it is often used off-label both intravenously and intranasally. A transdermal sufentanil patch called Transdur-sufentanil is currently in Stage I clinical trials by ENDO pharmaceuticals for the relief of chronic pain, and has the advantage over fentanyl patches such as Duragesic of only needing to be applied once per week.
It is essential for the administering doctor to be trained in airway management with readily available airway equipment because the drug causes significant respiratory depression and may cause respiratory arrest if given too much too rapidly. Other opioid side effects such as heart rhythm irregularity, blood pressure changes and nausea/vomiting can also be present in patients given this drug and should be dealt with accordingly by the doctor or anesthetist.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sufentanil". A list of authors is available in Wikipedia.|